Is High Blood Pressure Genetic? What a 1-Million-Person Study Says About Your Risk Report

Is High Blood Pressure Genetic? What a 1-Million-Person Study Says About Your Risk Report

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: Blood pressure is strongly shaped by genes, but never by one gene. A 2024 genome study of 1,028,980 adults found 2,103 separate genetic signals for blood pressure. Yet the 2025 AHA/ACC guideline states that all genetic sites found so far explain under 10% of why blood pressures differ. So a consumer risk report is a prompt to measure, not a diagnosis. A validated cuff, confirmed outside the clinic, is what decides.

What you’ll learn

• Why blood pressure has no single “hypertension gene”, and what 2,103 genetic signals actually mean.
• Why a 16.9 mmHg gap between the top and bottom tenth of a score is not a forecast for you.
• What a direct-to-consumer report can and cannot say, and why the FDA has not reviewed it.
• What large studies say about effort, diet and salt at every level of genetic risk.

There is no single “high blood pressure gene”

Most people picture one faulty gene handed down like eye colour. Blood pressure does not work that way.

Start with the plumbing. Blood pressure is set by how hard the heart pushes and how much the arteries resist. Three systems do most of the tuning: artery muscle tone, kidney handling of salt and water, and a hormone loop called the renin-angiotensin-aldosterone system.

The US National Heart, Lung, and Blood Institute states the genetics plainly. High blood pressure “often runs in families”, it says, and “many genes are linked to small increases in high blood pressure risk”.

What a million-person genome scan found

In 2024, a team led by Keaton JM published the largest single-stage genome scan of blood pressure so far. It examined 1,028,980 people of European ancestry. It resolved 2,103 separate genetic signals, of which 113 had never been reported. Secondary analyses pointed to 500 genes not previously tied to blood pressure.

That is what polygenic means: many genes, each adding a tiny nudge, rather than one gene deciding the outcome. The opposite pattern is a single-gene disease such as cystic fibrosis, where one gene drives the condition.

The two numbers you must not merge

Here is the pair that trips up almost every article on this topic. Both numbers are correct. They measure different things.

• Keaton’s signals explain more than 60% of SNP-based heritability. SNP-based heritability is the share of differences that can be traced to common single-letter changes in DNA. It is a slice of the pie, not the whole pie.
• The 2025 AHA/ACC guideline says that “all genetic loci described to date explain <10% of BP variance”. Here the denominator is the whole pie: every reason one person’s pressure differs from another’s.

So scientists have captured most of the common-variant signal. That signal still accounts for less than a tenth of the spread. Genes do not explain most of your blood pressure.

Named genes, honestly labelled

Two genes come up again and again. ATP2B1 encodes a calcium pump involved in artery muscle tone. A 2009 scan found it was the only site reaching genome-wide significance for hypertension itself. NPR3 encodes a clearance receptor for vessel-relaxing hormones. It appeared in a 2011 East Asian scan but did not replicate there, so it stays an unsettled signal.

Neither gene is “the” high blood pressure gene. Neither is inherited as a dominant condition.

What a polygenic result is not:

• It is not a diagnosis of any disease.
• It is not carrier status, a term that belongs to single-gene conditions.
• It is not a pathogenic variant, and there is no “variant of uncertain significance” to reclassify.
• It is not a 50-percent coin flip for each child.

If a report has unsettled you, bring the printout to your primary care clinician rather than acting on it alone.

Section recap: Blood pressure is polygenic, so thousands of common variants each add a small amount. The 2024 scan captured over 60% of the common-variant signal, yet that signal explains under 10% of why pressures differ.

How much does a polygenic score actually move the needle?

This is where the topic’s most quotable number lives. It is also the most misread.

In Keaton’s validation dataset, people in the top tenth of the score differed from people in the bottom tenth by 16.9 mmHg of systolic pressure. Those tenths are called deciles, the ten equal slices you get when you rank everyone by score. The same comparison gave an odds ratio of 7.33 for high blood pressure. An odds ratio compares the odds of a condition in one group with the odds in another. So 7.33 means the odds were more than seven times higher at the top.

Why that is not a forecast for you

A decile gap describes the distance between two large groups. It does not describe one man on one Tuesday morning.

The National Human Genome Research Institute is blunt about this. A polygenic score “can only explain the relative risk for a disease”, and such scores “do not provide a baseline or timeframe”. They “only show correlations, not causations”, and they “will always be probabilities, not certainties”.

There is a second honest measure in the same 2024 paper. Adding the score to a prediction model raised the AUROC from 0.791 to 0.826. AUROC is a 0-to-1 measure of how well a model separates people who develop a condition from people who do not. A gain of 0.035 is real but modest. It is an improvement, not a transformation.

Translate it into people out of 100

Absolute risk means how many people out of 100 actually have the condition. That is the number worth holding on to.

The CDC’s National Center for Health Statistics surveyed US adults from August 2021 to August 2023. It found 47.7% had high blood pressure, defined as 130/80 mmHg or above, or already taking blood-pressure drugs. That is roughly 48 out of every 100 adults. The figure is threshold-dependent, and older reports used 140/90 mmHg, which gives a lower number.

US adults (2021-2023)	Share with high blood pressure	Out of 100 people
All adults 18+	47.7%	about 48
Men	50.8%	about 51
Women	44.6%	about 45
Ages 18-39	23.4%	about 23
Ages 40-59	52.5%	about 53
Ages 60 and older	71.6%	about 72

Source: NCHS Data Brief No. 511.

Read the age rows again. Moving from your thirties to your fifties more than doubles the share affected. The NHLBI explains why: vessels naturally thicken and stiffen with age. Age moves the number far more than any score percentile does.

So an “increased likelihood” line lands on top of a baseline that is already close to a coin flip for middle-aged adults. It is a nudge, not a verdict.

A separate US study of 21,897 adults measured effects per standard deviation of score rather than by decile. That is a different contrast, not a competing estimate of the same quantity. Your clinician can put any report in the context of your own numbers.

Section recap: The 16.9 mmHg figure is a gap between population tenths, not a personal prediction. About 48 out of 100 US adults already meet the 130/80 definition, so age and measurement matter more than a percentile.

The rare exception: single-gene high blood pressure and its red flags

There is one setting where genetics really does change treatment. It is uncommon, and a consumer report will never detect it.

A small minority of high blood pressure is monogenic, meaning a single gene is responsible. A 2025 review in the American Journal of Hypertension describes these disorders as “caused by single-gene mutations that are typically inherited in an autosomal dominant fashion”. Autosomal dominant means one altered copy, from either parent, is enough. The review lists familial hyperaldosteronism, Gordon syndrome, Liddle syndrome, apparent mineralocorticoid excess, congenital adrenal hyperplasia, Geller syndrome, and inherited pheochromocytoma syndromes. Several types of familial hyperaldosteronism are recognised, and the naming is still settling.

Liddle syndrome is the clearest example. MedlinePlus Genetics, from the NIH, states it “is caused by mutations in the SCNN1B or SCNN1G gene”. Those genes build parts of the kidney’s epithelial sodium channel. Faulty channels are not cleared properly, so too much salt is reabsorbed, pressure rises and potassium falls. It is “inherited in an autosomal dominant pattern” and causes “severe hypertension that begins unusually early in life, often in childhood”.

Notice the contrast. A real 50-percent-per-child coin flip exists here. It does not exist for a polygenic score.

Red flags that make a clinician think about a single-gene cause:

• High blood pressure starting in childhood, the teens or the early twenties.
• Severe pressure, or pressure that resists three or more drugs.
• Unexplained low potassium, or an unusual blood acid-base pattern.
• A strongly affected family across generations, with early onset.
• Abnormal sexual development or a related syndrome alongside the pressure.

Why it matters is practical, not academic. The same review notes that “treating each form of monogenic hypertension requires specific and targeted treatment approaches”. Finding one of these changes the drug, not just the label. Confirmation needs a clinician-ordered sequencing panel, not a consumer array.

Say this part twice, because readers conflate it constantly. A polygenic “increased likelihood” is not a reason to suspect a single-gene form. If the red flags describe your family, start with your primary care clinician, who can refer you onward. The National Society of Genetic Counselors lists members at findageneticcounselor.nsgc.org, which it calls a directory rather than a referral service.

Section recap: Rare single-gene forms such as Liddle syndrome are truly inherited, and finding one changes the drug choice. A consumer polygenic report does not screen for any of them.

What your 23andMe report can and cannot tell you

Now look at the product itself. Accuracy here matters more than comfort.

23andMe lists High Blood Pressure among its reports “Powered by 23andMe Research”, alongside atrial fibrillation, coronary artery disease and others. The company explains the method in its own words. These reports “take into account hundreds or thousands of genetic markers that all have a small impact on likelihood for a condition”.

The FDA fine print

The company’s own disclaimer is the key sentence. Its set includes “reports that meet FDA requirements for genetic health risks and reports which are based on 23andMe research and have not been reviewed by the FDA”. High Blood Pressure sits in the second group.

The company also lists every approval and clearance it holds, covering carrier status, BRCA1/2, pharmacogenetics and others. High blood pressure appears nowhere on that list. So the report is not FDA-cleared, and no phrasing should suggest otherwise.

Two access details matter. The report needs the Premium Ancestry + Health membership at USD 99 per year, plus the V5 chip. In July 2025, the TTAM Research Institute acquired the Personal Genome Service assets, and the site now operates as 23andMe Research Institute. Terms are worth re-reading when a company changes hands, though the release said existing privacy policies remain in effect. All pages accessed 2026-09-26.

The ancestry limit, stated properly

This is the biggest caveat, and it is measurable rather than vague.

A 2019 analysis found that polygenic scores “available today are several times more accurate in individuals of European ancestry than other ancestries”. It calls that “an inescapable consequence of Eurocentric biases” in such studies. The NHGRI agrees that accuracy “may only be valid and useful for European ancestry populations” today.

Keaton’s discovery sample was entirely European-ancestry. The paper did test its signals elsewhere and found clear links in a large African-American sample. Still, the same printed percentile does not mean the same thing for every reader.

What the report is and is not:

• It is a weighted sum across many common variants, reported as a likelihood band or percentile.
• It is not reviewed by the FDA, and not a test result to act on.
• It is not used by either 2025 hypertension guideline, as the next section explains.
• It is a reasonable conversation starter for your next appointment.

One clarification that prevents a common mix-up. This article is about the control of blood pressure itself: vessel tone and kidney salt handling. Coronary artery disease is about fat and inflammation in the artery wall. Atrial fibrillation is about electrical remodelling of the upper heart chambers. Hypercholesterolemia, meaning high LDL cholesterol, is likewise a separate genetic story from blood pressure. High blood pressure is a major modifiable risk factor for the first two, so the topics are linked even though the genetics are separate.

The American Heart Association reviewed polygenic scores for heart disease in 2022. It offered only “provisional guidance”. Notably, high blood pressure was not among the five conditions it selected.

Section recap: The High Blood Pressure report is a research-derived polygenic score that the FDA has not reviewed. Its accuracy is best proven in people of European ancestry. Treat it as a prompt for a clinician visit.

The test that actually decides: a validated cuff, not a gene chip

Blood pressure is diagnosed by measurement. That has not changed, and nothing in a DNA file changes it.

The US Preventive Services Task Force gives blood-pressure screening its highest grade. It “recommends screening for hypertension in adults 18 years or older with office blood pressure measurement”. That is a Grade A rating, its strongest. The task force also recommends “obtaining blood pressure measurements outside of the clinical setting for diagnostic confirmation before starting treatment”. No comparable recommendation exists for genetic screening for high blood pressure.

The numbers, with the guideline attached

The 2025 AHA/ACC guideline kept the categories used since 2017.

Category (2025 AHA/ACC)	Systolic	Diastolic
Normal	under 120	and under 80
Elevated	120-129	and under 80
Stage 1 hypertension	130-139	or 80-89
Stage 2 hypertension	140 or above	or 90 or above

Source: 2025 AHA/ACC guideline, Top Take-Home Message 4.

Stage 1 means the milder band, 130-139 systolic or 80-89 diastolic. Stage 2 means 140 or above systolic, or 90 or above diastolic. A pharmacy reading of 138/86 would fall in stage 1 if confirmed properly.

Canada now uses the same definition. The 2025 Hypertension Canada primary care guideline defines high blood pressure as “BP >= 130/80 mm Hg when measured with a validated device under optimal conditions”. It says it moved to align with other international guidelines.

Where the two countries genuinely differ

The definitions agree. Treatment thresholds do not.

• United States. Drug therapy is recommended at an average systolic of 130 mmHg or above. That applies to adults with diabetes, chronic kidney disease, or a 10-year risk of 7.5% or more on the PREVENT calculator. For lower-risk adults, drugs are recommended if systolic stays at 130 or above after a three-to-six-month lifestyle trial.
• Canada. Drug treatment is recommended at 140/90 mmHg or above, and at systolic 130-139 only for adults at high risk of heart and vessel disease. High risk there means established heart disease, diabetes, chronic kidney disease, a 10-year Framingham risk of 20% or more, or age 75 and above. Hypertension Canada states that the benefit of treating lower-risk adults in that band “is uncertain”.
• Starting drugs. In the US guideline, starting with two agents in a single pill is the stage 2 recommendation; for stage 1 a single first-line drug “is reasonable”. Canada recommends low-dose combination therapy as initial treatment more broadly.

Neither guideline mentions polygenic scores anywhere in diagnosis, risk assessment or treatment. That absence is verified, not assumed.

How to take readings that count

One kiosk reading settles nothing. White-coat hypertension, where pressure rises only in a clinical setting, affects 15% to 30% of people with a high office reading. Masked hypertension, where pressure is normal in the office but high elsewhere, has a rate of 10% to 15%.

The 2025 AHA/ACC home protocol is specific:

• Use a validated device and the right cuff size. The American Medical Association maintains a US validated device listing at validatebp.org.
• Avoid smoking, caffeine or exercise for 30 minutes beforehand.
• Sit for at least five minutes, feet on the floor, legs uncrossed, back supported.
• Put the cuff on a bare arm, supported at heart level, and do not talk or use your phone.
• Take two readings one minute apart, twice a day, for four daily readings.
• Do this for three days at minimum, and seven days preferably, before your appointment.

Two practical notes. Cuffless devices, including wrist-worn gadgets, are rated “No Benefit” by the 2025 AHA/ACC guideline for diagnosis or management. Canadian readers can use the Hypertension Canada recommended device list instead. Bring the written log to your clinician, who decides what it means.

Section recap: A validated cuff with out-of-office confirmation makes the diagnosis, not a gene chip. The US and Canada now share the 130/80 definition, but they set different thresholds for starting drugs.

Does anything you do still matter? Yes, at every level of genetic risk

This is the question a risk report really raises. It has an unusually clean answer.

In 2018, researchers studied 277,005 UK Biobank adults aged 40-69 with no prior heart and vessel disease. They built a genetic risk score from 314 blood-pressure sites. They also built a lifestyle score covering body-mass index, diet, alcohol, smoking, salt excretion and sedentary time.

People were split into tertiles, three equal slices of the ranked group. Take the most favourable lifestyle tertile against the least favourable. Systolic pressure was lower by 3.6, 3.5 and 3.6 mmHg in the low, middle and high genetic-risk groups. Cardiovascular events were lower by 30%, 33% and 31% across the same three groups.

Look at the pattern rather than any single figure. The benefit was near identical in every genetic stratum. The P value for interaction on events was 0.99, meaning the benefit showed no detectable dependence on genetic risk. That test asks whether an effect differs between groups, and here it found no difference.

A separate US study of 21,897 adults, 35.8% of them not White, found the same shape. Among people with a high blood-pressure genetic score, a favourable risk-factor profile was linked to a 58% lower hazard of heart and vessel events than an unfavourable one. A similar pattern appeared at intermediate and low genetic risk.

Both are observational cohorts, not randomised trials. They show associations, and promise no individual a specific drop. The 2018 authors were careful themselves, writing that the “advantages and disadvantages of disclosing genetic predisposition to high BP for risk stratification needs careful evaluation”. A published correction to that paper exists.

The randomised anchor

For causal evidence, look at DASH-Sodium. It randomised 412 people to a control diet or the DASH diet, each at high, intermediate and low salt levels. Now compare the control diet at high salt with the DASH diet at low salt. The DASH arm gave systolic pressure “7.1 mm Hg lower in participants without hypertension, and 11.5 mm Hg lower in participants with hypertension”. The effects held across sexes and racial groups.

The guideline grades each target. Class 1 means it is recommended outright, and Level A means the strongest grade of evidence. Class 2a is a step down, meaning the step can be useful.

Targets from the 2025 AHA/ACC guideline:

• Sodium: below 2,300 mg a day, moving toward an ideal limit below 1,500 mg (Class 1, Level A).
• Alcohol: abstinence is now the stated goal, or at most one drink a day for women and two for men (Class 1, Level A).
• Weight: at least a 5% reduction in body weight where relevant (Class 1, Level A).
• Potassium: 3,500 to 5,000 mg a day from food.
• Potassium-based salt substitutes can be useful, except with kidney disease or drugs that raise potassium (Class 2a).
• Activity: aerobic exercise plus resistance training. Section 4 of the guideline gives 150 minutes a week of moderate activity plus resistance work on two or more days.

Hypertension Canada sets no numbers of its own here, saying the committee “chose not to specify particular interventions” so that personal values and preferences can apply. Numbers quoted above belong to the US guideline, not to Canada.

None of this is an alternative to prescribed medication. It sits alongside whatever your clinician recommends, and only your clinician can change a prescription.

Section recap: In 277,005 adults, a better lifestyle went with about 3.5 mmHg lower systolic pressure. Heart and vessel events fell by roughly a third, in every genetic-risk tertile. A high score shifts the starting point, not the return on effort.

2024-2026: two new drug mechanisms, and what they are for

Treatment news moved recently, so dates and regulators matter in every sentence here.

Aprocitentan is an endothelin receptor antagonist, which blocks a hormone signal that tightens blood vessels. Baxdrostat is an aldosterone synthase inhibitor, which blocks production of a salt-retaining hormone. Both are add-on drugs. Neither is first-line, and no genetic or polygenic result selects anyone for either.

	Aprocitentan (Tryvio)	Baxdrostat (Baxfendy)
Class	Endothelin receptor antagonist	Aldosterone synthase inhibitor
FDA approval	March 19, 2024	May 15, 2026
Use	Add-on, pressure not controlled on other drugs	Add-on, pressure not controlled on other drugs
Boxed warning	Yes, embryo-fetal toxicity	None
Health Canada	Authorized as JERAYGO	Not found in the register

Sources: FDA and Health Canada records, accessed 2026-09-26.

Aprocitentan, stated accurately

The FDA approved aprocitentan on March 19, 2024. The label indicates it “in combination with other antihypertensive drugs” for adults “not adequately controlled on other drugs”.

It carries a boxed warning, the strongest warning the FDA can place on a drug label. The warning covers embryo-fetal toxicity and remains in force on the current label. The drug must not be used in pregnancy.

One correction matters here. The drug was originally distributed under a REMS, a restricted programme requiring certified prescribers. That REMS was removed in April 2025, after the FDA determined it was no longer necessary. The boxed warning stayed; the prescriber restriction did not. The drug is not restricted-distribution today.

Now the effect size, reported the honest way. The phase 3 PRECISION trial randomised 730 patients already on three blood-pressure drugs including a diuretic. At week four, office systolic fell by about 15 mmHg on aprocitentan. It also fell by 11.5 mmHg on placebo. The placebo-corrected difference, which is the drug’s actual contribution, was -3.8 and -3.7 mmHg for the two doses. Quoting the 15 mmHg alone overstates the drug roughly fourfold.

Swelling or fluid retention was the most frequent adverse event, at 9% and 18% by dose versus 2% on placebo. Idorsia Pharmaceuticals and Janssen Biotech funded the trial.

Health Canada has authorized aprocitentan, but under the brand name JERAYGO rather than Tryvio. The register shows no recorded marketing date, so “authorized” is accurate and “available” is not.

Baxdrostat, and why it is not the same

The FDA approved baxdrostat on May 15, 2026, with AstraZeneca announcing it on May 18. The indication is again add-on therapy for adults not adequately controlled on other agents. It is described as the first-in-class aldosterone synthase inhibitor.

Its label carries no boxed warning and no REMS. Aprocitentan’s boxed warning does not apply to it, and mixing up the two would be a serious error.

The phase 3 BaxHTN trial randomised 796 patients whose pressure stayed at 140 to under 170 systolic despite two or more drugs. At week 12, seated systolic fell 15.7 mmHg on the 2 mg dose and 5.8 mmHg on placebo. The placebo-corrected difference was -9.8 mmHg. Potassium above 6.0 mmol/L occurred in 3.0% on 2 mg versus 0.4% on placebo, and high potassium is the known class risk. This was a 12-week trial using a pressure endpoint. It did not show fewer heart attacks, strokes or deaths. AstraZeneca funded the trial.

As of 2026-09-26, no Health Canada authorization for baxdrostat was found in the Drug Product Database.

Two more items, labelled clearly

The 2025 AHA/ACC guideline lists renal denervation as an adjunct that “may be considered” for selected patients with resistant hypertension. That means pressure staying high despite optimal treatment. It is not a standard option.

Zilebesiran is investigational, with no FDA approval and no Health Canada authorization. Its phase 2 KARDIA-3 results were reported by Alnylam on 2025-08-30 and presented at the ESC Congress that year. A single 300 mg dose gave a placebo-adjusted systolic reduction of 5.0 mmHg at month 3, with a nominal p-value of 0.0431. The rule required both doses below 0.05, or one dose below 0.025. Neither condition was met, so the trial missed its pre-specified definition of statistical significance. There is no peer-reviewed publication of KARDIA-3.

Only your prescriber can decide whether any of this applies to you. Never start, stop or change a blood-pressure drug on the basis of an article.

Section recap: Aprocitentan and baxdrostat are genuinely new add-on mechanisms, with placebo-corrected effects of about 3.8 and 9.8 mmHg. Aprocitentan keeps a boxed warning but lost its REMS in April 2025; baxdrostat has neither.

Family, insurance, and what to bring to your next appointment

Two practical questions follow any susceptibility result. Most explainers answer both badly.

Your family

Cascade testing is the standard workflow for single-gene conditions, where relatives are tested for one known family variant. It does not transfer to a polygenic score, because there is no single variant to test for.

Collect something more useful instead. A written family blood-pressure history changes clinical decisions in a way a percentile does not.

What to write down for each close relative:

• Whether they have high blood pressure, and the age it was first found.
• What blood-pressure drugs they take, if any.
• Any stroke, heart attack, kidney disease or pre-eclampsia, and at what age.
• Any very early onset, in childhood or the early twenties, which is a red flag.

Your paperwork

Insurance is where accuracy really pays. The Genetic Information Nondiscrimination Act of 2008, known as GINA, is the US law here.

• Health insurance. GINA’s protections “extend to private health insurers, Medicare, Medicaid, Federal Employees Health Benefits, and the Veterans Health Administration”.
• Employment. GINA “does not apply to employers with fewer than 15 employees”.
• The gap. GINA’s protections “do not cover long-term care insurance, life insurance, or disability insurance”. Some states add protections in those lines.

Canada works differently, and the two systems are not equivalent. The Genetic Non-Discrimination Act of 2017 makes it an offence to require a genetic test. The same applies to demanding results as a condition of a contract, good or service. Penalties run up to a $1,000,000 fine or five years in prison. The Supreme Court of Canada upheld the Act on July 10, 2020, in a 5-4 decision. Canada’s statute is criminal law with no equivalent insurance carve-out.

One clarification saves a lot of confusion. A blood-pressure reading already in your medical record, or a prescription you already take, is ordinary medical information. It is not genetic information. Neither law changes what a life insurer may ask about it.

Bring these four things to your appointment:

• The written family history described above.
• Seven days of home readings taken to protocol, four readings a day.
• Your full medication and supplement list.
• One specific question, such as whether your confirmed numbers put you in stage 1 and what that means for you.

That package is what changes a visit. A percentile is not. Everything here is educational information, and your clinician remains the person who interprets it.

Section recap: There is nothing for relatives to be tested for, so share the family history instead of the score. GINA covers health insurance and larger employers, but not life, disability or long-term-care insurance.

Frequently asked questions

Will I get high blood pressure?

Nobody can tell you that from a score. Here is the baseline: about 48 out of 100 US adults already meet the 130/80 definition, and about 53 out of 100 at ages 40 to 59. A high score shifts your position on that curve, but it sets no date. A week of measured readings, discussed with your clinician, tells you far more.

Will my children inherit it?

Not in the 50-percent coin-flip sense, because there is no single variant to pass on. What travels is a broad tendency shaped by thousands of small effects. What helps them is the family pattern, the ages of onset, and their own pressure checked on their clinician’s schedule.

Will this affect my health or life insurance?

For US health insurance, GINA bars private insurers, Medicare and Medicaid from using genetic information. For life, disability and long-term-care insurance, it does not apply. One point trips people up: a blood-pressure number already in your chart is ordinary medical information, not genetic information.

Can my employer find out?

GINA bars employers from using genetic information in hiring, promotion or terms of employment. It does not apply to employers with fewer than 15 employees. In Canada, requiring a genetic test or its results as a contract condition is a criminal offence. The two regimes are not equivalent, so check which applies to you.

Should I get a second opinion?

For a polygenic report, the more useful step is a first clinical opinion rather than a second genetic one. Bring the printout and your home readings to primary care. If the single-gene red flags in this article describe your family, ask about a referral to a medical geneticist or a board-certified genetic counselor.

Summary

Blood pressure genetics is now mapped in remarkable detail. A 2024 study of 1,028,980 adults resolved 2,103 separate signals and captured over 60% of the common-variant heritability. Its headline 16.9 mmHg gap between the top and bottom tenth describes two large groups, never one person.

Hold that next to the deflationary number. All genetic sites found so far explain under 10% of why blood pressures differ. Neither 2025 guideline uses a polygenic score for anything.

What decides is measurement. A validated cuff, used to protocol and confirmed outside the office, is the accepted entry point. Effort still counts at every level of genetic risk, as 277,005 UK adults and 21,897 US adults both suggest. Treatment has advanced too, with two new add-on mechanisms approved since 2024.

The science has become very precise about populations. It remains imprecise about people. That is exactly why the cuff still decides.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. Keaton JM, Kamali Z, Xie T, et al. Genome-wide analysis in over 1 million individuals of European ancestry yields improved polygenic risk scores for blood pressure traits. Nat Genet. 2024;56(5):778-791. https://pubmed.ncbi.nlm.nih.gov/38689001/
2. Pazoki R, Dehghan A, Evangelou E, et al. Genetic Predisposition to High Blood Pressure and Lifestyle Factors. Circulation. 2018;137(7):653-661. https://pubmed.ncbi.nlm.nih.gov/29254930/
3. Fryar CD, Kit B, Carroll MD, Afful J. Hypertension Prevalence, Awareness, Treatment, and Control Among Adults Age 18 and Older: United States, August 2021-August 2023. NCHS Data Brief No. 511. https://www.cdc.gov/nchs/data/databriefs/db511.pdf
4. Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/multisociety Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults. Hypertension. 2025;82(10):e212-e316. https://www.ahajournals.org/doi/10.1161/HYP.0000000000000249
5. Goupil R, Tsuyuki RT, Santesso N, et al. Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care. CMAJ. 2025;197(20):E549-E564. https://www.cmaj.ca/content/197/20/E549
6. O’Sullivan JW, Raghavan S, Marquez-Luna C, et al. Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2022;146(8):e93-e118. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001077
7. National Human Genome Research Institute. Polygenic Risk Scores. Accessed 2026-09-26. https://www.genome.gov/Health/Genomics-and-Medicine/Polygenic-risk-scores
8. National Heart, Lung, and Blood Institute. High Blood Pressure: Causes and Risk Factors. Accessed 2026-09-26. https://www.nhlbi.nih.gov/health/high-blood-pressure/causes
9. Gallegos FR, Delahunty MP, Hu J, et al. Decoding Monogenic Hypertension: A Review of Rare Hypertension Disorders. Am J Hypertens. 2025;38(6):333-351. https://pubmed.ncbi.nlm.nih.gov/39803890/
10. MedlinePlus Genetics, National Library of Medicine. Liddle syndrome; Familial hyperaldosteronism. Accessed 2026-09-26. https://medlineplus.gov/genetics/condition/liddle-syndrome/
11. US Food and Drug Administration, NDA 217686, TRYVIO (aprocitentan); Health Canada Drug Product Database, JERAYGO. Accessed 2026-09-26. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfe7a2ee-612c-4aba-834a-d68e6b59a0a6
12. Schlaich MP, Bellet M, Weber MA, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION). Lancet. 2022;400(10367):1927-1937. https://pubmed.ncbi.nlm.nih.gov/36356632/
13. US Food and Drug Administration, NDA 219878, BAXFENDY (baxdrostat); AstraZeneca media centre. Accessed 2026-09-26. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1fc1ee7-facc-4099-b3db-a4c1daeaa4be
14. Flack JM, Azizi M, Brown JM, et al. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025;393(14):1363-1374. https://pubmed.ncbi.nlm.nih.gov/40888730/
15. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the DASH diet. N Engl J Med. 2001;344(1):3-10. https://pubmed.ncbi.nlm.nih.gov/11136953/
16. Krist AH, Davidson KW, Mangione CM, et al. Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2021;325(16):1650-1656. https://pubmed.ncbi.nlm.nih.gov/33904861/
17. National Human Genome Research Institute. Genetic Discrimination; Genetic Non-Discrimination Act, S.C. 2017, c. 3; Reference re Genetic Non-Discrimination Act, 2020 SCC 17. Accessed 2026-09-26. https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination
18. Martin AR, Kanai M, Kamatani Y, et al. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet. 2019;51(4):584-591; and Parcha V, Pampana A, Shetty NS, et al. Circ Genom Precis Med. 2022;15(6):e003946. https://pubmed.ncbi.nlm.nih.gov/30926966/
19. Levy D, Ehret GB, Rice K, et al. Genome-wide association study of blood pressure and hypertension. Nat Genet. 2009;41(6):677-687; and Kato N, Takeuchi F, Tabara Y, et al. Nat Genet. 2011;43(6):531-538. https://pubmed.ncbi.nlm.nih.gov/19430479/
20. American Medical Association US Blood Pressure Validated Device Listing; Hypertension Canada recommended devices; NSGC Find a Genetic Counselor. Accessed 2026-09-26. https://www.validatebp.org/
21. Alnylam Pharmaceuticals. Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial (KARDIA-3 results). 2025-08-30. https://investors.alnylam.com/press-release?id=29246
22. 23andMe Customer Care. About Premium Ancestry + Health; 23andMe and the FDA. Accessed 2026-09-26. https://support.23andme.org/hc/en-us/articles/42966331365399-About-Premium-Ancestry-Health

Last updated: 2026-09-26

Author: genelumen editorial team. This article aggregates 22 sources from peer-reviewed medical literature and public health agencies (tier 1 = 14, tier 2 = 6). Sources include NIH, CDC/NCHS, FDA, Health Canada, the USPSTF, the 2025 AHA/ACC guideline, and the 2025 Hypertension Canada guideline.

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada) or 119 (Japan).

Related: Genetic Diseases category

🌐 日本語版: https://genelumen.com/ja/ja-metabolic-hematologic-genetic/hypertension-polygenic-risk-japan